|
Incidence of venous thromboembolism and adverse events among medical inpatients receiving enoxaparin versus UFH prophylaxis |
|||
| Prophylaxis Received [N(%)] |
|||
|
|
|||
| Outcome |
Enoxaparin (N = 479) |
UFH (N = 2,837) |
RR (95% CI) |
|
|
|||
| DVT |
8 (1.7) |
163 (5.8) |
0.29 (0.14, 0.59) |
| PE |
0 (0.0) |
32 (1.1) |
0 |
| VTE (DVT and/or PE) |
8 (1.7) |
180 (6.3) |
0.26 (0.13,0.53) |
| Adverse Events: |
|||
| HIT |
0 (0.0) |
0 (0.0) |
-- |
| Major Bleed |
12 (2.5) |
72 (2.5) |
0.99 (0.54,1.80) |
| Death |
25 (5.2) |
142 (5.0) |
1.04 (0.69, 1.58) |
|
DVT = deep-vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism; HIT = heparin-induced thrombocytopenia | |||
McGarry et al. Thrombosis Journal 2006 4:17 doi:10.1186/1477-9560-4-17 |
|||